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Abstract
Although the prevalence of Bordetella parapertussis varies dramatically among studies in different populations with different
vaccination regimens, there is broad agreement that whooping cough vaccines, composed only of B. pertussis antigens,
provide little if any protection against B. parapertussis. In C57BL/6 mice, a B. pertussis whole-cell vaccine (wP) provided
modest protection against B. parapertussis, which was dependent on IFN-c. The wP was much more protective against an
isogenic B. parapertussis strain lacking O-antigen than its wild-type counterpart. O-antigen inhibited binding of wP–induced
antibodies to B. parapertussis, as well as antibody-mediated opsonophagocytosis in vitro and clearance in vivo. aP–induced
antibodies also bound better in vitro to the O-antigen mutant than to wild-type B. parapertussis, but aP failed to confer
protection against wild-type or O antigen–deficient B. parapertussis in mice. Interestingly, B. parapertussis–specific
antibodies provided in addition to either wP or aP were sufficient to very rapidly reduce B. parapertussis numbers in mouse
lungs. This study identifies a mechanism by which one pathogen escapes immunity induced by vaccination against a closely
related pathogen and may explain why B. parapertussis prevalence varies substantially between populations with different
vaccination strategies.
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Introduction
Whooping cough is an acute, highly contagious, paroxysmal
coughing illness [1]. The first whooping cough vaccines consisting
of whole inactivated B. pertussis were licensed in the mid-1940s and
led to a dramatic decrease of disease incidence [1,2]. However, the
potential health risk associated with whole cell vaccines led to the
development of acellular vaccines, consisting of some combination
of B. pertussis antigens including pertussis toxin (PT), pertactin,
filamentous hemaglutinin (FHA) and 2 fimbriae serotypes. Despite
maintenance of high vaccine coverage, the reported whooping
cough incidence has been increasing over the past 20 years in
some developed countries [3,4], although a large portion of
whooping cough infections are thought to remain unreported [5].
Both B. pertussis and B. parapertussis are causative agents of
whooping cough [1,6] that appear to have evolved independently
from distinct lineages of B. bronchiseptica through rearrangements
and large scale gene loss, with B. parapertussis emerging more
recently than B. pertussis [7,8]. Although they are closely related, a
few striking differences exist between the human-adapted
bordetellae. For example, B. parapertussis lipopolysaccharide (LPS)
includes a repetitive membrane-distal O-antigenic structure, while
B. pertussis only expresses lipid A and a branched-chain core
oligosaccharide with a complex trisaccharide modification, but
lacks O-antigen [9,10]. B. pertussis expresses PT, but B. parapertussis
does not due to mutations in the promoter region [11,12]. Since
differential diagnosis of B. pertussis and B. parapertussis does not
affect the course of treatment, it is rarely performed in clinical
settings [13,14]. The CDC does not list B. parapertussis as
reportable [3], but a few epidemiological studies have reported
the percentage of whooping cough cases caused by B. parapertussis
to be from 1% to 98%, most commonly 4–40% [13]. Although B.
parapertussis appears to contribute substantially to disease, whoop-
ing cough vaccines are solely derived from B. pertussis [1].
Clinical and experimental data indicate that whooping cough
vaccines are very efficacious against B. pertussis but not against B.
parapertussis [14–18], however, a mechanistic understanding of this
phenomenon has not been described. While whooping cough
vaccines may fail to generate efficient cross-immunity against B.
parapertussis, it is also possible that cross-reacting adaptive
immunity is generated but is evaded by B. parapertussis. Recently,
our lab showed that the O-antigen of B. parapertussis shields it from
B. pertussis-infection-induced antibodies [19], relevant to the
natural immune-mediated competition between B. pertussis and
B. parapertussis in unvaccinated population. However, nearly all
people in industrialized countries are vaccinated, changing the
immune landscape of the host population and the immune-
mediated competition between these two human pathogens.
To examine the mechanisms used by B. parapertussis to evade B.
pertussis vaccines-induced immunity, we showed that a B. pertussis whole
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(aP) had no effect against B. parapertussis growth in mouse lungs. IFN-c
contributes to the protection against B. parapertussis by wP. O-antigen
shielded B. parapertussis from the binding of vaccine-induced antibodies,
interfered with opsonophagocytosis of B. parapertussis mediated by aP
and wP-induced antibodies and blocked antibody-mediated clearance
in vivo. wP conferred more protection against an isogenic B. parapertussis
strain lacking O-antigen, indicating that O-antigen contributed to the
evasion of wP-induced immunity. aP, however, failed to induce cross-
protection against B. parapertussis with or without the hindrance of O-
antigen. In B. pertussis vaccinated hosts, supplement of B. parapertussis-
specific, but not B. pertussis-specific, antibodies conferred protection
against B. parapertussis, indicating that the lack of proper antibody
responses causes the failure of these vaccines against B. parapertussis.
Together these results explain the clinical finding that B. parapertussis
avoids clearance by the current vaccines, and provides a mechanistic
understanding that will guide new approaches to overcoming this
problem.
Materials and Methods
Bacterial strains and growth
B. pertussis strain 536, B. parapertussis strain CN2591 and its
isogenic mutant lacking O-antigen, CN2591Dwbm, have been
described previously [10,20]. For opsonization, attachment and
phagocytosis experiments, these strains were transformed with
plasmid pCW505 (kindly supplied by Dr. Alison Weiss, Cincinnati,
Ohio) which induces cytoplasmic expression of GFP without
affecting growth, or antigen expression [21]. Bacteria were
maintained on Bordet-Gengou agar (Difco) supplemented with
10% sheep’s blood (Hema Resources) and 20 mg/mL streptomy-
cin (Sigma-Aldrich). Liquid cultures were grown overnight in
Stainer-Scholte broth at 37uC to mid-log phase [22,23].
Cells
Peripheral blood polymorphonuclear leukocytes (PMNs) were
isolated from heparinized venous blood using Ficoll-Histopaque
(Sigma, St Louis, MO) gradient centrifugation. PMNs were harvested
and the remaining erythrocytes were removed by hypotonic lysis. Cell
viability was .99% as determined by Trypan Blue exclusion. Prior to
functional assays, PMNs were washed twice with Dulbecco’s modified
Eagle medium (DMEM) (Hyclone) supplemented with 10% of fetal
calf serum (FCS) (Hyclone), resuspended, and used immediately. All
experiments were carried out with freshly isolated PMNs lacking
FccRI (CD64) expression, as monitored by FACS analysis using a
fluorescence-activated cell sorter FACScan (Becton Dickinson, San
Jose, CA) with anti-FccRI mAb 22 [24].
Opsonization
GFP-expressing strains were opsonized by incubation at 37uC
with 5% heat-inactivated wP-induced/naive or aP/adjuvant-
induced serum samples for 30 min in a final volume of 50 mL.
Serum opsonized bacteria were incubated with R-phycoerythrin
(RPE)–labeled goat F(ab9)2 fragments of anti-mouse IgG (Southern
Biotechnology, Birmingham, AL) for 30 min at 4uC. Opsonization
of each Bordetella strain was determined by FACS analysis [25].
Attachment and phagocytosis
Attachment and phagocytosis of the Bordetella strains were
evaluated as previously described with a few modifications [26].
Briefly, serum opsonized GFP-expressing bacteria were incubated
with PMNs at multiplicity of infection (MOI) of 30 for 20 min at
37uC to allow binding. After extensive washing to remove non-
attached bacteria, an aliquot was maintained on ice to be used for
bacterial attachment control. Another aliquotwasfurtherincubated
for1hat37uCtoallowinternalization.Phagocytosiswasstoppedby
placing PMNs on ice. Cell surface bound bacteria in both aliquots
(before and after 1 hour incubation at 37uC) were detected by
incubation with RPE–labeled goat F(ab9)2 fragments of anti-mouse
IgG at 4uC for 30 min. To avoid eventual nonspecific binding of
antibodies, all incubations were done in the presence of 25% heat-
inactivated human serum. After washing, samples were analyzed by
flow cytometry. Ten thousand cells were analyzed per sample.
Green fluorescence intensity associated with PMNs maintained at
37uC for 20 min has previously been shown to represent bacterial
attachment [25]. Phagocytosis was calculated from the drop in
mean red fluorescence intensity of green-positive cells after
incubation for additional1h at 37uC as described [25].
Animal experiments
C57BL/6 mice were obtained from Jackson Laboratories (Bar
Harbor) and bred in our Bordetella-free, specific pathogen-free
breeding rooms at The Pennsylvania State University. 4–6 week
old mice were sedated with 5% isoflurane (Abbott Laboratory) in
oxygen and vaccinated by intraperitoneally (i.p.) injection of
1610
8 CFU of heat-inactivated bacteria in 1 mL of phosphate
balanced saline (PBS, Omnipur) (wP), 1/5 human dose of Adacel
(Sanofi Pastuer) (0.5 mg PT, 1 mg FHA, 0.6 mg pertactin, 5 mg
fimbriae 2 and 3 per mouse) with Imject Alum (Thermo Scientific)
(aP) or only Imject Alum in 200 mL PBS on day 14 and 28 prior to
challenge [27]. For challenge, mice were sedated and inoculated
by pipetting 50 mL PBS containing 5610
5 CFU of the indicated
bacteria onto the external nares [28]. This method reliably
distributes the bacteria throughout the respiratory tract [29]. For
adoptive transfer of immune serum, mice were vaccinated with the
indicated bacteria on day 0 and 14 and sera were collected on day
28 or sera were collected from naı ¨ve animals. 200 mL of sera were
i.p. injected at the time of inoculation [30,31]. For quantification
of bacteria numbers, mice were sacrificed via CO2 inhalation and
the lung, trachea, and nasal cavity were excised. Tissues were
homogenized in PBS, serial diluted and plated onto Bordet-
Gengou agar plates with 20 mg/mL streptomycin, and colonies
were counted after incubation at 37uC for 3–5 days [30]. Gamma
interferon (IFN-c) was depleted by i.p. injections of 5 mg of the
antibody from hybridoma XMG1.2 one day prior to challenge
[32]. The lower limit of detection was 10 CFU. For all
experiments, protocols were reviewed and approved by the
Pennsylvania State University IACUC and all animal were
handled in accordance with institutional guidelines.
Splenocyte re-stimulations
Spleens were excised from groups of 3–4 C57BL/6 mice after
vaccination. Splenocytes were isolated as previously described
[27,33]. In brief, spleens were homogenized and red blood cells
were lysed with 0.84% ammonium chloride. 2610
6 cells were re-
suspended in DMEM supplemented with 10% FCS, 1 mM sodium
pyruvate (HyClone), and 100 mg/mL penicillin and streptocycin
(HyClone)andplacedinto each well ofa 96-well tissue culture plate.
Splenocytes were stimulated with either media alone or media
containing 10
7 CFU (MOI of 5) of the indicated bacteria that had
been heat-killed [27,33]. After three days, the supernatants were
collected and analyzed for IFN-c and interleukin-10 (IL-10)
production via Enzyme-linked immunosorbent assays (ELISA) as
per the manufacturers’ instructions (R&D Systems).
Titer ELISAs
Antibody titers were determined as previously described
[19,34,35]. Briefly, heat-inactivated or exponential phase live
parapertussis Evades Vaccine
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7 CFU/mL in a 1:1 mix of 0.2 M
sodium carbonate and 0.2 M sodium bicarbonate buffers. These
antigens were coated onto 96-well plates, incubated for 2 h at
37uC in a humidified chamber, washed and blocked. A1:50 or
1:10 dilution of wP-induced/naive or aP/adjuvant-induced serum
samples from an individual mouse was added to the first well of
each row and serially diluted 1:2 across the plates. Plates were
incubated for 2 h at 37uC, washed and probed with 1:4000
dilution of goat anti-mouse Ig horseradish peroxidase (HRP)-
conjugated antibodies (Southern Biotech) for 1 h and visualized
with 2,29-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) dia-
mmonium salt in phosphate-citrate buffer with hydrogen peroxide
at an absorbance of 405 nm. Titers were determined via the
endpoint method based on optimal density of identically treated
wells probed with naı ¨ve or adjuvant-induced sera.
Western blot analysis
Lysates containing 5610
5 CFU of indicated heat-killed bacteria
were run on 7% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels in denaturing conditions. Poly-
vinylidene Fluoride (PVDF) membranes (Millipore) were probed
overnight with either naı ¨ve serum or serum from vaccinated mice
at a 1:10 or 1:100 dilution for aP and wP-induced serum
respectively. 1:10,000 dilution of goat anti-mouse Ig HRP-
conjugated antibodies (Southern Biotech) was used as the detector
antibody [19,36]. The membrane was visualized with ECL
Western Blotting Detection Reagent (Pierce Biotechnology).
Statistical analysis
The means +/2 standard error (error bars) were determined for
all appropriate data. Two-tailed, unpaired Student’s T-tests were
used to determine statistical significance between groups. Results
were also analyzed by ANOVA and Tukey simultaneous test in
Minitab with similar significance. All experiments were performed
at least twice with similar results.
Results
B. parapertussis O-antigen contributes to the evasion of
wP–induced immunity
To examine whether wP is cross-protective against B.
parapertussis and whether O-antigen interferes with its cross-
protection, naı ¨ve or wP vaccinated C57BL/6 mice were
challenged with 5610
5 CFU of B. pertussis, B. parapertussis or an
Figure 1. B. parapertussis is more susceptible to wP–induced immunity in the absence of O-antigen. Groups of four naı ¨ve (black) or wP
vaccinated (white) C57BL/6 mice were challenged with the indicated bacteria. (A) The number of CFUs recovered from the respiratory tract on day 3
post-challenge is expressed as the Log10 mean 6 the standard error. Decreases in Log10CFU in vaccinated mice compared to naı ¨ve mice on day 3
post-challenge are indicated underneath the x axes. (B) The change in CFU number over the first 3 days after challenge is expressed as change in
Log10 mean 6 the standard error. * indicates P#0.05. ** indicates P#0.01. The limit of detection is indicated as the lower limit of the y axes.
doi:10.1371/journal.pone.0006989.g001
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comparison to naı ¨ve mice, wP treatment reduced B. pertussis
numbers by 91.9%, 97.8% and .99.9% in the nasal cavity,
trachea and lungs by day 3 post challenge; naı ¨ve mice having
about 7000 fold more bacteria in the lungs than vaccinated mice
(Figure 1A). wP vaccination reduced B. parapertussis loads by
76.6%, 83.0% and 97.6% in the nasal cavity, trachea and lung;
naı ¨ve mice having about 40 fold more bacteria in the lungs than
vaccinated mice (Figure 1A). These results are consistent with
multiple clinical studies showing whole cell vaccines confer good
protection against B. pertussis but relatively little protection against
B. parapertussis [16,17,37]. Interestingly, compared to naı ¨ve mice,
wP reduced numbers of an O-antigen deficient B. parapertussis
strain by 89.4%, 99% and .99.9% in the nasal cavity, trachea
and lung; naı ¨ve mice having around 2000 fold more bacteria in
the lungs than vaccinated mice (Figure 1A). The fold protection
(reduction of bacterial number in each individual vaccinated
mouse compared to mean number of bacteria in naive mice on
day 3 post-challenge) of wP against O-antigen deficient B.
parapertussis was significantly higher than against wild-type B.
parapertussis in both trachea and lung (lung: P=0.0006, trachea:
P=0.018), indicating that wP is more efficacious against O-
antigen deficient B. parapertussis.
To understand how vaccination affects the infection, it is
important to examine these effects in the context of the dynamic
infectious process. B. pertussis and B. parapertussis increased in
numbers throughout the respiratory tract of naı ¨ve mice over 3
days, reflecting effective colonization and bacterial growth
(Figure 1B). O-antigen deficient B. parapertussis grew in the nasal
cavity and trachea but not in the lungs of naı ¨ve mice due to its
increased susceptibility to complement [38] (Figure 1B). wP
decreased the numbers of B. pertussis in all respiratory organs over
3 days, resulting in a net decline in numbers, particularly in the
lower respiratory tract (LRT). Vaccination did not decrease B.
parapertussis numbers as efficiently in the lung and B. parapertussis
actually grew in numbers in the trachea and nasal cavity, reflecting
successful colonization and expansion despite vaccination
(Figure 1B). Interestingly, wP vaccination decreased O-antigen
deficient B. parapertussis numbers as efficiently as it did B. pertussis
numbers in the trachea and lung (Figure 1B). Together these
results are consistent with clinical studies showing that wP
vaccination confers relatively little protection against B. parapertussis
and show that O-antigen is required for B. parapertussis to avoid
efficient wP vaccine-induced immunity.
Many developed countries have switched to acellular vaccines,
although these provide even less protection against B. parapertussis
[16,18,37]. We therefore determined if the O-antigen of B.
parapertussis contributes to the evasion of aP-induced immunity.
While aP reduced B. pertussis colonization in both lung and trachea
of vaccinated mice by 99.7% and 96.8% compared to the mice
given just adjuvant, aP had no effects on either B. parapertussis or
O-antigen deficient B. parapertussis colonization (Figure 2). These
data indicate that aP does not induce protective immunity against
B. parapertussis.
wP induces T cells that cross react with B. parapertussis
To investigate why aP is less effective than wP against B.
parapertussis and why wP confers different levels of protection
against B. pertussis, O-antigen deficient and wild-type B. paraper-
tussis, we compared their induction of T cell responses known to be
important for control and clearance of B. parapertussis [34].
Splenocytes from mice that were naı ¨ve, vaccinated with wP, aP
or adjuvant were stimulated with heat-killed B. pertussis or wild-
type or O-antigen deficient B. parapertussis. After 3 days, IFN-c and
IL-10 production, representative of TH1 and TH2 responses, was
measured. aP vaccination did not affect IFN-c or IL-10 levels,
which were similar to those induced by naı ¨ve and adjuvant-treated
controls (Figure 3). In contrast, splenocytes from wP-vaccinated
mice responded similarly to heat-killed B. parapertussis or B. pertussis,
producing significantly higher IFN-c and IL-10 than splenocytes
from naı ¨ve or adjuvant-treated mice (Figure 3). IFN-c and IL-10
production was abolished in TCRb/d
2/2 mice (data not shown),
indicating that vaccine-induced IFN-c and IL-10 production is
dependent on T cells. These data indicate that the T-cell response
to wP is cross-reactive to B. parapertussis and that O-antigen did not
affect the T cell response.
IFN-c contributes to wP–induced protection against B.
parapertussis
In the vaccination studies above (Figure 1, Figure 2), protection
against B. parapertussis correlates with the high IFN-c responses of
wP but not aP vaccinated animals (Figure 3). IFN-c has been
shown to contribute to leukocyte recruitment and the reduction of
bacterial numbers during B. parapertussis infection (D.N. Wolfe,
A.T. Karanikas, S.E. Hester, M.J. Kennett, E.T. Harvill,
submitted for publication). To determine how the cross-reactive
IFN-c response after wP vaccination might contribute to its
protection against B. parapertussis, naı ¨ve or wP vaccinated mice
Figure 2. aP does not reduce B. parapertussis numbers. Groups of
four C57BL/6 mice were vaccinated with adjuvant only (black) or aP
(white), challenged with the indicated bacteria and sacrificed on day 3
post-challenge. The numbers of CFUs recovered from the respiratory
tract are expressed as the Log10 mean 6 the standard error. ** indicates
P#0.01. The limit of detection is indicated as the lower limit of the y
axes.
doi:10.1371/journal.pone.0006989.g002
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pertussis or B. parapertussis and sacrificed 3 days later for bacterial
enumeration. Vaccination or IFN-c depletion had no effects on
colonization of the nasal cavity (Figure 4). However, B. pertussis
numbers were reduced by .99.9% and .99.5% in the lung and
trachea of vaccinated mice compared to naı ¨ve mice regardless of
the presence or absence of IFN-c (Figure 4). Although wP reduced
B. parapertussis numbers in the lung and trachea by about 98.6%
and 99.6%, this effect was abolished in mice given IFN-c
neutralizing antibodies (Figure 4), indicating that IFN-c contrib-
utes to the protection conferred by wP against B. parapertussis.
Serum antibody responses to aP and wP are cross-
reactive to denatured but not live B. parapertussis
We have previously shown that antibodies are required for
anamnestic immunity to B. parapertussis [34]. To determine whether
B. pertussis vaccines induce antibodies that recognize and/or protect
against B.parapertussis,we firsttested whetherantibody responsesare
cross-reactive between strains and if O-antigen affects the
responsiveness of antibodies. In a western blot, whole cell extracts
of B. pertussis, wild-type and O-antigen deficient B. parapertussis were
probed with serum antibodies from aP, adjuvant only, wP
vaccinated or naı ¨ve mice. Compared to the control, aP vaccination
induced serum antibodies that recognized distinct antigens present
in all three bacteria, although the size and intensity of bands
appeared to differ between B. pertussis and B. parapertussis. While wP-
induced serum antibodies recognized four major bands in
denatured B. parapertussis, they recognize more antigens in B.
pertussis, especially those of high molecular weights (Figure 5A).
To quantify the cross-reactivity of antibodies, we determined
the titers of aP or wP-induced serum antibodies by ELISA using
heat-inactivated bacteria as antigens. wP-induced sera had much
higher titers than aP-induced sera (Figure 5B). For both aP and
wP-induced serum antibodies, B. pertussis-specific antibody titers
were much higher than B. parapertussis-specific antibody titers
regardless of the presence or absence of O-antigen (Figure 5B).
Since heat killing releases many antigens that are not exposed on
the surface of live bacteria, similar experiments were performed
with live bacteria as antigens. Interestingly, both wP and aP-
induced serum antibodies bound to live B. parapertussis more
efficiently in the absence of O-antigen (Figure 5C). These data
suggest that O-antigen interferes with the binding of B. pertussis
vaccine-induced antibodies to live B. parapertussis.
O-antigen inhibits aP– and wP–induced, antibody-
mediated opsonization and subsequent attachment to,
and phagocytosis by, PMNs
To determine whether O-antigen interferes with key functions
of antibodies, we assessed its effects on opsonization and
subsequent attachment to and phagocytosis by PMNs mediated
Figure 3. Splenic production of IFN-c and IL-10 is cross-reactive. Splenocytes from groups of four naı ¨ve C57BL/6 mice or mice vaccinated
with the indicated vaccine were stimulated with media only (vertically hatched), heat-killed B. pertussis (black), B. parapertussis (white) or O-antigen
deficient B. parapertussis (horizontally hatched) for 3 days. The concentration of IFN-c and IL-10 in the supernatant is expressed as the mean 6 the
standard error. ND indicates none detected.
doi:10.1371/journal.pone.0006989.g003
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(Figure 5C), B. pertussis was efficiently opsonized by both aP and
wP-induced serum antibodies (Figure 6A, 6B, and 6D). Although
B. parapertussis was efficiently opsonized by whole cell B. parapertussis
(wPP)-induced serum antibodies (Figure 6C and 6D), aP or wP-
induced antibodies failed to opsonize this bacterium (Figure 6A,
6B, and 6D). In contrast, O-antigen deficient B. parapertussis was
efficiently opsonized by aP or wP-induced antibodies (Figure 6A,
6B, and 6D), indicating that O-antigen hinders the opsonization of
B. parapertussis by both aP and wP-induced serum antibodies.
To examine if O-antigen blocking of opsonization results in
inhibitory effects on attachment of B. parapertussis to phagocytes,
bacteria opsonized with vaccine-induced antibodies were further
incubated with polymorphonuclear leukocytes (PMN) for 20 mins
and cell surface bound bacteria numbers were identified by flow
cytometry. aP or wP-induced-antibody-opsonized B. pertussis
attached to PMNs efficiently (Figure 7A, 7B, and 7D). B.
parapertussis attached to PMN after opsonization with wPP-induced
serum antibodies (Figure 7C and 7D), but neither aP nor wP-
induced antibodies mediated attachment of this bacterium to
PMNs (Figure 7A, 7B, and 7D). B. parapertussis lacking O-antigen,
opsonized with aP or wP-induced antibodies, efficiently attached
to phagocytes (Figure 7A, 7B, and 7D), indicating that O-antigen
also inhibits this process.
To determine if O-antigen interferes with aP or wP-induced
antibodies ability to mediate phagocytosis of B. parapertussis by
PMNs, an aliquot of cells from the attachment experiment was
incubated for one extra hour and phagocytosis was measured. No
significant internalization of naı ¨ve serum-opsonized bacteria was
observed. B. pertussis opsonized with aP or wP-induced antibodies
was efficiently phagocytosed, but similarly treated B. parapertussis
was not (Figure 8). In contrast, wPP-induced antibody-opsonized
B. parapertussis was efficiently internalized by PMNs (Figure 8). B.
parapertussis lacking O-antigen opsonized by aP or wP-induced
antibodies was efficiently phagocytosed by PMNs. Together these
results indicate that O-antigen protects B. parapertussis from aP or
wP-induced serum antibody mediated opsonization, attachment to
phagocytes and subsequent internalization by these cells.
O-antigen blocks antibody-mediated clearance of B.
parapertussis from mouse lungs
Since O-antigen interferes with the binding of B. pertussis
vaccine-induced antibodies to live B. parapertussis and phagocytosis
dependent on these antibodies in vitro, we tested if O-antigen
inhibits antibody-mediated clearance in vivo. Serum from naı ¨ve
(NS), wP- or wPP-vaccinated mice were transferred to naı ¨ve
animals. Bacterial loads in the lungs were determined on day 14
post B. parapertussis challenge since antibodies have no effect until
B. parapertussis specific T cell responses are generated around day
14 [30,39] (D.N. Wolfe unpublished data). Serum from wPP
vaccinated animals significantly lowered numbers of both wild-
type and O-antigen deficient B. parapertussis compared to naı ¨ve
serum treated animals and modestly reduced B. pertussis numbers
(Figure 9). This indicates that although lower level of phagocytosis
of O-antigen deficient B. parapertussis mediated by wPP-induced
serum antibodies were observed compared to wild-type strain
(Figure 8), this low level of phagocytosis and/or other biological
activities of passively transferred antibodies might be sufficient to
reduce O-antigen deficient strain in vivo (Figure 9). wP-induced
serum completely cleared B. pertussis from the lung by day 14 post-
challenge but did not reduce B. parapertussis numbers. These serum
antibodies did, however, reduce the numbers of O-antigen
deficient B. parapertussis by more than 90% (Figure 9), indicating
that O-antigen prevents the wP-induced serum antibody mediated
reduction of B. parapertussis numbers in vivo.
B. parapertussis–specific antibodies augment B. pertussis
vaccine-induced protective immunity against B.
parapertussis
We have previously shown that both antibodies and T cells are
required for anamnestic protective immunity against B. parapertussis
[34]. Although wP vaccination induced T cell responses that were
cross-reactive (Figure 4) and antibodies that bound antigens from
heat-killed B. parapertussis (Figure 5B), O-antigen decreased the
binding of these antibodies to live B. parapertussis (Figure 5), the
opsonophagocytosis mediated by these antibodies in vitro (Figure 6,
Figure 7, Figure 8) and their antibody-mediated clearance in vivo
(Figure 9). Based on these observations, we hypothesized that wP
induces sufficient T cell response but the antibody response is not
Figure 4. IFN-c contributes to the protection against B.
parapertussis by wP. Groups of four naı ¨ve (black and horizontally
hatched) or wP vaccinated (white and vertically hatched) C57BL/6 mice
were untreated (2) (black and white) or i.p. injected with (+)
(horizontally and vertically hatched) anti-IFN-c antibody, challenged
with B. parapertussis and sacrificed 3 days post-challenge. The number
of CFUs throughout the respiratory tract is expressed as the Log10 mean
6 the standard error. * indicates P#0.05. ** indicates P#0.01. The limit
of detection is indicated as the lower limit of the y axes.
doi:10.1371/journal.pone.0006989.g004
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e6989Figure 5. O-antigen inhibits the binding of B. pertussis vaccine-induced antibodies to live, but not denatured, B. parapertussis cells.
(A) Western blots were performed on lysates of indicated bacteria probed with serum antibodies collected from mice that were vaccinated with aP,
adjuvant only (Adj) or wP. (B) Heat-inactivated or (C) live B. pertussis (black), B. parapertussis (white) or O-antigen deficient B. parapertussis (hatched)
were coated on ELISA plate. Serum antibody titer of mice vaccinated with aP or wP is expressed as mean of the end point titers of four independent
samples 6 the standard error. ** indicates P#0.01. The dashed line indicates the limit of detection.
doi:10.1371/journal.pone.0006989.g005
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parapertussis from wP-induced antibodies. If this were the case, then
adding antibodies that bind live B. parapertussis should render wP
induced immunity sufficient to rapidly clear B. parapertussis. To test
this, mice were vaccinated with aP (Figure 10A) or wP
(Figure 10B), these vaccinated mice were left untreated or given
naı ¨ve, wP or wPP-induced serum antibodies at the time of B.
parapertussis challenge and sacrificed three days after challenge. To
compare the protective immunity to that generated by B.
parapertussis, a group of mice were vaccinated with wPP and
adoptively transferred with wPP-induced antibodies. Less than 100
CFUs of B. parapertussis were recovered in the LRT of this group of
mice by day 3 post-challenge (Figure 10B). The very high titers of
this wPP-induced serum antibodies alone had modest effect on
reducing B. parapertussis numbers (Figure 10B), consistent with
prior results with convalescent serum [30,39]. In both aP and wP
vaccinated mice, naı ¨ve sera had no effect, indicating that
components in the serum other than those induced by vaccination
do not affect bacteria numbers. Transfer of wP-induced sera had
no effect on B. parapertussis colonization throughout the respiratory
tract. However, B. parapertussis numbers were significantly lower in
the LRT of both aP and wP vaccinated animals given wPP-
induced sera than in those given naı ¨ve sera (Figure 10). These data
suggest that the addition of B. parapertussis specific antibodies is
sufficient to render wP and aP effective against B. parapertussis.
Discussion
The increasing incidence of whooping cough in highly vaccinated
developed countries includes an unknown proportion of B. parapertussis
infections[3,4]. Multiple clinical and experimental studies have shown
that current whooping cough vaccines have little efficacy against this
bacterium [14–18], but have not revealed why. In this study, we
determined that O-antigen shields vaccine-induced antibodies from
binding to B. parapertussis and prevents antibody-mediated opsonopha-
gocytosis in vitro and antibody-mediated clearance in vivo.A l t h o u g hO -
antigen requires a large multigenic wbm locus to produce and B. pertussis
is still successful in the human population without this surface antigen
[40], it is retained in B. parapertussis [7]. Apart from its role in inhibiting
Figure 6. O-antigen decreases the opsonization of B. paraper-
tussis by B. pertussis vaccine-induced antibodies. Representative
histograms show flow cytometric analysis of indicated bacteria
opsonized with naı ¨ve serum (white) or (A) aP, (B) wP, (C) wPP-induced
serum (grey) and stained with RPE-labeled goat F(ab)2 fragments of
anti-mouse IgG. (D) Mean red-fluorescence of B. pertussis (black), B.
parapertussis (white), O-antigen deficient B. parapertussis (hatched)
opsonized with indicated serum from four individual mice 6 the
standard error is shown. AU indicates arbitrary units. ** indicates
P#0.01.
doi:10.1371/journal.pone.0006989.g006
Figure 7. O-antigen blocks B. pertussis vaccine-induced anti-
bodies from mediating adherence of B. parapertussis to PMNs.
Naı ¨ve serum (white) or (A) aP, (B) wP, (C) wPP-induced serum (grey)-
opsonized GFP-expressing bacteria were incubated with freshly isolated
human peripheral blood PMNs. Representative histograms of flow
cytometry analysis of these cells are shown. (D) Mean green
fluorescence associated with PMNs incubated with GFP-expressing B.
pertussis (black), B. parapertussis (white) or O-antigen deficient B.
parapertussis (hatched) opsonized with four independent indicated
serum 6 the standard error is shown. AU indicates arbitrary units. **
indicates P#0.01.
doi:10.1371/journal.pone.0006989.g007
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body-mediated phagocytosis of B. parapertussis. Freshly isolated
human peripheral blood PMNs were incubated for 20 min or 1 h and
20 min with GFP-expressing B. pertussis (black), B. parapertussis (white),
or O-antigen deficient B. parapertussis (hatched), that are opsonized
with serum from aP, wP, wPP-vaccinated or naı ¨ve mice. The cell surface
bound bacteria were detected by incubation with RPE-labeled goat
F(ab’)2 fragments of anti-mouse IgG. Mean phagocytosis calculated
from the decrease in red-fluorescence of green-positive cells incubated
for 1 h and 20 min compared to that incubated for 20 min of
experiments done with 4 independent serum samples 6 the standard
error was shown. AU indicates arbitrary units. ** indicates P#0.01.
doi:10.1371/journal.pone.0006989.g008
Figure 9. Passive transfer of wP–induced serum antibodies
mediates clearance of O-antigen deficient, but not wild-type, B.
parapertussis from mouse lungs. Groups of four C57BL/6 mice were
adoptively transferred naı ¨ve serum (black), wP-induced serum (white) or
wPP-induced serum (hatched) at the time of bacterial challenge and
dissected 14 days later. The number of CFUs recovered from lung is
expressed as the Log10 mean 6 the standard error. * indicates P#0.05
and ** indicates P#0.01 compared to mice given naı ¨ve serum. The limit
of detection is indicated as the lower limit of the y axes. ND indicates
undetectable bacterial number.
doi:10.1371/journal.pone.0006989.g009
Figure 10. Passive transfer of B. parapertussis–specific antibodies rapidly reduces B. parapertussis colonization in aP and wP
vaccinated animals. Groups of four C57BL/6 mice were (B) left untreated (2) or vaccinated with (A) aP, (B) wPP or wP. Mice lacking a transfer of
antibodies (2) or given naı ¨ve serum (NS), wP-induced serum (wP IS) or wPP-induced serum (wPP IS) were challenged with B. parapertussis. Mice were
sacrificed three days post-challenge and the number of CFUs recovered from the respiratory tract is expressed as the Log10 mean 6 the standard
error. ** indicates P#0.01. The limit of detection is indicated as the lower limit of the y axes.
doi:10.1371/journal.pone.0006989.g010
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study suggests that O-antigen, by decreasing B. pertussis-vaccine-
induced antibody binding, may confer a selective advantage to B.
parapertussis i nh u m a np o p u l a t i o n si nw h i c ht h e r ei sh i g hp r e v a l e n c eo f
detectable immunity to B. pertussis.
It is interesting that wP, but not aP, induced IFN-c, which
contributed to protection against B. parapertussis but not B. pertussis
(Figure 4). IFN-c plays a role in the recruitment and activation of
phagocytic cells [41,42]. In B. parapertussis infected mice, the peak of
neutrophil numbers in the lung on day 7 and subsequent control of
B. parapertussis numbers are dependent on IFN-c (D.N. Wolfe, A.T.
Karanikas, S.E. Hester, M.J. Kennett, E.T. Harvill, submitted for
publication). B. pertussis challenged IFN-c
2/2 mice, however, have
an indistinguishable course of infection in the respiratory tract and
recruit similar numbers of leukocytes to the site of infection as
compared to wild-type mice [43] (Wolfe unpublished data),
indicating that IFN-c is not required for B. pertussis clearance and
leukocyte recruitment. In vaccinated IFN-cR
2/2 mice, no
impaired reduction of B. pertussis numbers is observed during the
first week after challenge, although a rebound of bacteria number
was observed on day 10 [44]. This is consistent with ourobservation
that IFN-c is not required forvaccine-mediated control ofB. pertussis
numbers on day 3 post-challenge (Figure 4).
Consistent with multiple clinical and experimental studies, we
found that while wP confers some level of protection against B.
parapertussis, aP does not [16,18]. The decrease of pertussis
acellular vaccines efficacy against B. parapertussis compared to
whole cell vaccines has been suggested to be attributable to the
failure of antibodies induced by pertussis acellular vaccines to
block the adherence of B. parapertussis to epithelial cells [45] or the
immune suppressive effects of the FHA included in those vaccines
[46]. Among the antigens included in the aP, only fimbriae, but
not FHA and pertactin, was shown to confer cross-protection
against B. parapertussis in a mouse model [37,47]. wP contains more
antigens than aP, among which there may be cross-protective
antigens. Alternatively, the differences in Th1/Th2 skewing of wP
and aP may affect vaccine efficacy. wP induces a relatively
balanced Th1/Th2 response whereas aP induces a Th2-type
response [48]. Our data showed that wP, but not aP, induced high
splenic IFN-c production and wP was no longer protective against
B. parapertussis when IFN-c was depleted, suggesting that IFN-c
contributes to the protection conferred by wP (Figure 3, Figure 4).
These data are therefore consistent with the idea that inducing a
Th1 response enhances immunity against B. parapertussis. The
different Th1/Th2 skewing, quantity and quality of cross-reactive
antibodies and possible immune suppression factors in aP may also
explain why aP vaccination was not sufficient to induce protection
against B. parapertussis even without the hindrance by O-antigen.
Our data reveal an interesting paradox. wP-mediated clearance
of B. parapertussis by day 3 requires IFN-c, which aP does not
induce (Figure 3, Figure 4). Yet when wPP-induced antibodies,
which had limited effect in naı ¨ve animals in the first week of
infection (Figure 10B) [30], were given to aP-vaccinated animals,
B. parapertussis was effectively cleared from mouse lungs within 3
days (Figure 10A). IFN-c appears to contribute to the protection
conferred by wP, but aP-vaccination contributes to rapid clearance
despite the lack of detectable IFN-c induction in our splenocyte re-
stimulation assay (Figure 3). It is possible that some low level of
IFN-c was induced by aP vaccination, which we failed to detect, or
some other cross-reactive protective T cell cytokine responses aid
in the rapid clearance mediated by B. parapertussis-specific
antibodies in aP-vaccinated animals.
Although it is not clear how much B. parapertussis contributes to
the resurgence of whooping cough, the low efficacy of current
vaccines against this bacterium might confer a selective advantage
to B. parapertussis, relative to B. pertussis. Moreover, the lower
protection against B. parapertussis conferred by acellular vaccines
than whole cell vaccine could affect the relative prevalence, a
possibility of greater significance since the recent switch from
whole cell to acellular vaccines and the even more recent
introduction of acellular vaccines, including the one used here,
for adolescents and adults [16,18,49,50]. Considering adults to be
a possible reservoir for transmission to infants [51,52], the lack of
cross-protection of Adacel, determined in this study, may open a
niche for B. parapertussis not only in adolescents/adults but also in
infants. This study shows that B. parapertussis evades B. pertussis
vaccine induced immunity by blocking cross-reactive antibodies
binding via O-antigen. Our current data provide strong evidence
that including more B. pertussis proteins that induce antibodies that
recognize orthologs in B. parapertusis is unlikely to improve vaccines
so that they protect against B. parapertussis. Since our study
indicates that supplementing wP or aP with B. parapertussis-specific
antibodies rendered them effective against B. parapertussis
(Figure 10), addition of protective antigens of B. parapertussis to
the vaccine may substantially improve its efficacy against this
pathogen.
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